SAN DIEGO, Jan. 12 /PRNewswire/ -- Trega Biosciences, Inc.
(Nasdaq: TRGA) today announced the appointment of Gerard A. Wills, as chief
financial officer. Mr. Wills will be responsible for corporate finance,
investor relations, corporate communications, information systems and
facilities and report to Michael G. Grey, president and chief executive
officer.
As Trega's chief financial officer, Mr. Wills brings approximately
20 years of experience in corporate financial management. Most recently he
served as vice president of finance and chief financial officer at Molecular
Biosystems, Inc. for six years. He was chief adviser to the chief executive
officer and chief operations officer on all corporate funding and business
development matters.
"Gerry's experience in business development and investor relations as well
as financial and strategic management makes him ideal as Trega's chief
financial officer," said Grey. "He will add great value to our senior
management team."
Trega Biosciences is a drug discovery company, utilizing combinatorial
chemistry and other technologies to pursue the discovery of novel,
small-molecule drug therapies. The company leverages its technology platform
by entering into pharmaceutical alliances, which provide partners with access
to Trega's technologies in exchange for licensing fees and potential
milestones and royalties, or by establishing joint-discovery alliances with
pharmaceutical and biotechnology companies. Trega also uses its drug
discovery technologies in its internal development programs, which are
currently focused on discovering small molecules acting on melanocortin
receptors. Melanocortins are a class of receptors which may be important in
the treatment of inflammatory and metabolic diseases.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether the impending transition in
management will occur without disrupting the Company's business and operation,
whether any proposed product can be successfully formulated, scaled-up,
developed, and commercialized, whether regulatory approvals can be obtained,
the impact of competitive products and pricing, the financial condition of the
Company in the future, whether any corporate collaborations or alliances will
be successful, and other risks detailed from time to time in Trega's
Securities and Exchange Commission filings. These forward-looking statements
represent Trega's judgment as of the date of this release. Actual results may
differ materially from those projected. Trega disclaims, however, any intent
or obligation to update these forward-looking statements.
SOURCE Trega Biosciences, Inc.
 back to top
Related links:
http://www.trega.com
Company News On-Call:
http://www.prnewswire.com/comp/374050.html or fax,
800-758-5804, ext. 374050
CONTACT:
Vince Reardon, Director of Corporate
Communications of Trega Biosciences, Inc., 619-410-6555
NOTE TO EDITORS: Trega's releases are on the World Wide Web at
http://www.trega.com and PR Newswire's fax-on-demand service at
1-800-758-5804, extension 374050
|
